The aim of the study was to investigate the multi-factorial phenomenon of possible postoperative thrombocytopenia after aortic valve replacement (AVR) with the freedom SOLO (FS) bioprosthesis. A total of 254 patients underwent AVR with FS bioprosthesis in two cardiac surgery institutes. Platelet counts were measured preoperatively, immediately postoperatively and daily until the 11th day postoperatively. A multivariate generalized estimating equation model was applied to identify prognostic factors for whether or not patients postoperative platelet counts indicated no thrombocytopenia ( platelet count >150 × 10 3 /mm 3
INTRODUCTION
In aortic valve replacement (AVR), pericardial stentless valves offer an attractive alternative to porcine stentless or stented valves [1] . The Pericarbon stentless valve (Sorin Group, Saluggia, Italy) has been available since 1991. A detoxification procedure was introduced in 2000 by the covalent binding of residual aldehyde groups to homocysteic acid aimed at enhancing biocompatibility [2] . Multiple studies have shown that the new generation prosthesis (Pericarbon Freedom stentless, Sorin Group) has excellent results after 3, 5 and 7 years of follow-up [3] . A modification of the valve, the Freedom SOLO (FS) [4] (Sorin Group) led to further improvement in haemodynamics [5] and has found general and wide acceptance after introduction in 2004. The implantation technique is strictly supra-annular with a single running suture line in the sinuses of Valsalva [6] . Few recent studies have analysed postoperative platelet count with the SOLO valve when compared with different valves [7] [8] [9] . All studies did report the absence of statistical significant difference in clinical events such as bleeding or thromboembolism compared with the control groups.
The aim of this retrospective analysis of combined cohort of 254 real-world patients implanted with the FS valve is to investigate the postoperative time course of patient platelet counts and the possible impact of prognostic factors on thrombocytopenia. Details of the implantation technique have been described elsewhere [1, 4] . Intraoperative echocardiogaphy was performed in all patients after weaning from extracorporeal circulation to ensure proper valve function. Complete and symmetric leaflet opening and the absence of paravalvular leakage were carefully evaluated.
MATERIALS AND METHODS

Between
While, in the intensive care unit, all the patients were treated with low-molecular-weight heparin s.c. for the first two postoperative days. On Day 3 postoperative, anticoagulant treatment was started.
Blood samples were collected and platelet count measured by haematological laboratories preoperatively, immediately postoperatively and daily from the first to the fifth and sixth day after the operation for Berlin and Brescia patients, respectively. Platelet count measurements were also obtained at discharge, with most patients (75%) being discharged by the eleventh postoperative day. The platelet count method in use at the centre, in the period of the study, was the Coulter LH 750 [7] .
The mean and standard deviation of platelet counts were calculated for each follow-up time ( preoperative, postoperative and from Day 1 to 11 The generalized estimating equation (GEE) regression method was applied to quantify how the odds of being in the group with postoperative platelet count <150 × 10 3 /mm 3 (mild, moderate, severe or very severe thrombocytopenia) versus no thrombocytopenia varies as a function of postoperative day and to identify prognostic factors for a patient experiencing or not experiencing thrombocytopenia (immediately postoperative and from Day 1 to 11) [10] . The expected non-linear relationship of the outcome to postoperative days (time) was investigated by including both a linear and a quadratic term for time in the GEE model.
P-values of <0.05 were considered significant. Statistical analyses were performed using SAS (Release 9.1, SAS Institute Inc., Cary, NC, USA).
RESULTS
Mean age was 75.8 ± 7.9 years. Surgery information including valve size, pump time and number of CABG performed is listed in Table 1 .
Platelet count information is reported in This period corresponds to heparin exposure, although it has not always been possible to detect whether there were phenomenon of antibody reactions.
Among patients with no preoperative thrombocytopenia, the lowest mean value of platelet count was 92.8 × 10 3 /mm 3 (SD: 58.3 × 10 3 /mm 3 ) at Day 3 after surgery when only two patients reached the very severe level (Table 2 and Figs 1 and 2 ). The lowest mean value for patients with mild or moderate preoperative thrombocytopenia was also reached at Day 3 after surgery, with only three reaching the very severe.
In addition to other published reports, we introduced and estimated the effect of prognostic factors on severity classes. Table 3 shows the results of the multivariate GEE analysis of the binomial model (using a logistic link function) evaluating the odds of being in the group with postoperative (immediately postoperative and from Day 1 to 11) platelet count <150 × 10 Table 3B reports the model-based estimates and observed probabilities of having thrombocytopenia by time. The modelbased estimated probabilities were calculated including in the multivariate model the mean values for each covariate (age at surgery: 75.8 years; valve size: ordinal average 2.555; pump time: 77.7 min; number of CABG: 0.5; proportion of patients with preoperative thrombocytopenia: 0.112). The result is called the 'least squares mean' estimated probability (LSM). The estimated probability of a patient having thrombocytopenia increases postoperatively until mid-way between Day 3 and 4, when the maximum estimated probability of having thrombocytopenia is 82.5%, and then starts to decrease reaching a probability lower than 50% at Day 9.
The clinical performance of FS was evaluated, and the outcomes showed no major haemorrhagic or thromboembolic event during hospitalization (Table 4 ). The haemodynamic performance was also evaluated in terms of peak and mean gradients, leading to the following results: peak pressure gradients for the more frequent implanted size was 16.8 ± 8.1 mmHg for 23 mm valve size and 14.0 ± 6.3 mmHg for 25 mm. Corresponding figures for mean pressure gradients were 9.1 ± 4.8 mmHg for 23 mm and 7.2 ± 3.6 mmHg for 25 mm.
DISCUSSION
The FS valve is a bovine pericardial stentless valve introduced in 2004 as a modification of the Pericarbon Freedom pericardial [4] . The modification consisted in a particular trimming aimed at eliminating the pericardial tissue below the cusps, in order to obtain a valve implantable with a single running suture line. Some published experiences [11] [12] [13] revealed differences in postoperative platelet count recovery depending on the implanted aortic valve prosthesis.
Although these observations support the association between platelet activation aggregation and bioprostheses, no clear cause-effect relationship was related to slower postoperative recovery of platelet levels which have been observed, even if at very different extent, in the above-mentioned studies [11] [12] [13] . A possible transient direct toxic effect on platelets originating from the FS valve has been suggested [12] -even in the absence of any evidence. A tissue treatment analysis report (Sorin Group internal documentation for CE marking) does not reveal any blood factors alterations and the tissue fully complies with the current ISO standards for biocompatibility.
A second possible explanatory factor could be the microhaemodynamic effects of the prosthetic structure depending on the implant technique. Implant technique has been already extensively used for the O'Brien Cryolife porcine stentless since 1987 [9] without any report of lower postoperative platelet levels after implantation.
It is well known that cardio-pulmonary by-pass (CPB) adversely affects both platelet count and function. Soon after starting CPB, platelet number rapidly decreases to 50% of the preoperative levels [10] . Moreover, elderly patients, with multiple comorbidities, who undergo acute platelet consumption during cardiac surgery, may have a very slow platelet recovery [14] . Platelet activation is the first step of the aggregation process which ultimately leads to platelet consumption. In case of early and late explanted prostheses, we did not find any abnormal leaflet thickening. The thrombocytopenia reported after implantation of the FS valve [12] revealed to be a transient phenomenon with recovery of platelet counts after 10-15 days, in the absence of any specific treatment.
As expected for patients after cardiac surgery, this study exhibited a large average drop in platelet count immediately after surgery and the decrease persisted through Day 3 after surgery. On average, the platelet count can be considered fully recovered after Day 7, when it returned to a healthy level (>150 × 10 3 /mm 3 ). The number of patients who during hospitalization experienced very severe thrombocytopenia was low and ranged from two patients at Day 1 and 5, to five patients at Day 3 and 4, and six patients at Day 2 after surgery. Preoperative thrombocytopenia was present in 11.2% of the patients and, except for the effect of time itself, was identified as the strongest predictor for the decrease in platelet count after surgery. A significant association between the valve size and the drop in platelet count was also suggested by the data. Patients with larger valve sizes had a decreased odds of having postoperative thrombocytopenia. This may be due in part to the flow turbulence typically present through all types of prosthetic valves and which is higher in the small sizes annulus.
Patients with no preoperative thrombocytopenia and larger implanted valve sizes were at decreased risk of having postoperative thrombocytopenia. Although not significant in the GEE model, increased age at surgery, longer pump time and a higher number of CABGs increased the risk of thrombocytopenia; this is as expected from the literature [9] . The effect of time itself was the most significant factor, with the model strongly indicating the increased risk of thrombocytopenia is a transient phenomenon.
Study patients showed no clinical consequences directly related to the platelet decrease. Moreover, no postoperative echocardiographic evidence of dysfunction was reported.
A word of caution must be used in defining thrombocytopenia as 'real' or that postoperative thrombocytopenia is a new phenomenon, since postoperative platelet count alone can be misleading due to its high variability and the evidence that preoperative values can strongly affect the postoperative course, at least in the first few weeks after surgery. The results of this study strongly support that postoperative thrombocytopenia is a transient phenomenon, self-recovering after a few days without any treatment and without any observed recurrence in late follow-up (including routine visits after discharge).
Since thrombocytopenia after aortic surgery is a complex and multi-factorial phenomenon, any consideration concerning possible influencing factors (i.e. type of bio-prosthesis) should be carefully studied along with other assessments in addition to using platelet counts.
We know that one of the main limitations of this study may be the lack of a control population with a different prosthesis, but since thrombocytemia after cardiac surgery is such a multifactorial phenomenon an eventual prospective randomized trial should regard a very large cohort of patients. Further studies are needed to clarify the physiopathological bases of platelet activation. As a general recommendation, in view of platelets consumption related to the many factors described, specific attention should be paid to thrombocytopenic patients undergoing any cardiac surgery procedure.
The high incidence of platelet reduction or pseudothrombocytopenia after FS valve implantation is for sure an interesting scientific subject to speculate on, but the limited number of mastered elements cannot impact on the clinically proven safety of the device as reported in the European Study [15] .
